Arbutus Biopharma Corporation ABUS Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's cumulative cost basis?
- Arbutus Biopharma Corporation (ABUS) reported cumulative cost basis of $71.53M in Q1 2026.
- How has Arbutus Biopharma Corporation's cumulative cost basis changed year-over-year?
- Arbutus Biopharma Corporation's cumulative cost basis decreased by 5.4% year-over-year, from $75.61M to $71.53M.
- What is the long-term trend for Arbutus Biopharma Corporation's cumulative cost basis?
- Over 3 years (2020 to 2025), Arbutus Biopharma Corporation's cumulative cost basis has grown at a 1.1% compound annual growth rate (CAGR), from $71M to $73.38M.